Table IV.
Multivariate analysis of the overall survival and clinical characteristics of patients with GC in the Nantong Cohort.
| Intestinal-type GC (n=172) | Diffuse-type GC (n=144) | Mixed-type GC (n=85) | ||||
|---|---|---|---|---|---|---|
| Variable | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age (≥65 vs. <65 years) | 0.95 (0.64–1.42) | 0.812 | 0.91 (0.61–1.37) | 0.659 | 1.19 (0.69–2.07) | 0.516 |
| Sex (Female vs. male) | 1.23 (0.79–1.91) | 0.357 | 0.81 (0.54–1.21) | 0.301 | 0.86 (0.49–1.51) | 0.603 |
| TNM stage | 2.06 (1.30–3.23) | 0.001a | 1.68 (0.99–2.84) | 0.053 | 1.49 (0.78–2.84) | 0.222 |
| CPS1 (High vs. low) | 2.38 (1.53–3.69) | 0.000a | 1.81 (1.22–2.71) | 0.003a | 1.92 (1.09–3.37) | 0.018a |
a
P<0.05. CPS1, carbamoyl phosphate synthetase 1; GC, gastric cancer; HR, hazard ratio; CI, confidence interval; TNM, Tumor-Node-Metastasis.